LUIS ORTIZ-ESPINOSA, M.D., FAAD
Dermatology Physician in CAROLINA, Puerto Rico. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
LUIS ORTIZ-ESPINOSA, M.D., FAAD reported a CMS MIPS final score of 0/100 — below the 83.1 national average — and filed 4,701 Medicare Part D claims in 2023.
- 0/100
- MIPS score · -83 vs avg
- 5K
- Part D claims, 2023
- 94%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
LUIS ORTIZ-ESPINOSA, M.D., FAAD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
0 0th percentile higher than 0% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
LUIS ORTIZ-ESPINOSA, M.D., FAAD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about LUIS ORTIZ-ESPINOSA, M.D., FAAD?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Puerto Rico
How Dermatology Physician compares to other specialties among Puerto Rico providers
Dermatology Physician share within Puerto Rico
Dermatology Physician is one of the more visible NUCC categories in Puerto Rico
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
LUIS ORTIZ-ESPINOSA, M.D., FAAD's 2023 MIPS final score plotted against the Dermatology Physician national average
- MIPS Final Score
- 0/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Dermatology Physician) — 0/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Dermatology Physician US NPIs
0/100 MIPS final score — 83.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Dermatology Physician. Quality dim: 0.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
LUIS ORTIZ-ESPINOSA, M.D., FAAD appears in the CMS NPPES registry as a Dermatology Physician provider holding M.D., FAAD credentials at PQ-28 AVE. EL COMANDANTE, CAROLINA, PR, 00983, with a listed phone of (787) 752-3280. NPI 1053390732 was issued on 01/11/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ORTIZ-ESPINOSA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 4,701 prescription claims written by this provider, covering 1,405 Medicare beneficiaries and totaling roughly $647K in drug spend, split 6% brand-name and 94% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 0/100 for the 2023 performance year (Quality 0), compared with the national average of 83.1.
Dermatology Physician is a mid-sized specialty nationwide, with 14,610 enrolled providers across 53 states and an average of 729 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1053390732 |
|---|---|
| Specialty | Dermatology Physician |
| Credentials | M.D., FAAD |
| Gender | Male |
| NPI Issued | 01/11/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm LUIS ORTIZ-ESPINOSA, M.D., FAAD's current license status, disciplinary history, and board certifications directly with the licensing state's medical board before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for LUIS ORTIZ-ESPINOSA, M.D., FAAD. Source: openpaymentsdata.cms.gov.
Total received
$2.0K
Largest payer
ABBVIE INC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Generic-heavy
6% brand-name claims vs 94% generic, on 4,701 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 4,865
- Total Day Supply
- 100,951
- Brand vs Generic
- 6% brand / 94% generic
- Brand Drug Cost
- $454K
- Generic Drug Cost
- $194K
- Antibiotic Claims
- 219
Patient Demographics
- Average Patient Age
- 71.7 years
- Avg HCC Risk Score
- 1.50
- Gender Split
- 70% female / 30% male
- Age Distribution
- <65: 206, 65-74: 684, 75-84: 403, 85+: 112
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What LUIS ORTIZ-ESPINOSA, M.D., FAAD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Mupirocin
Mupirocin
923 claims
- Ammonium Lactate
Ammonium Lactate
629 claims
- Clobetasol Propion…
Clobetasol Propionate
472 claims
- Ketoconazole 287
Ketoconazole
287 claims
- Betamethasone Vale… 199
Betamethasone Valerate
199 claims
- Fluocinolone Aceto… 173
Fluocinolone Acetonide
173 claims
- Ciclopirox 154
Ciclopirox
154 claims
- Hydrocortisone 136
Hydrocortisone
136 claims
| Drug | Claims |
|---|---|
| Mupirocin | 923 |
| Ammonium Lactate | 629 |
| Clobetasol Propionate | 472 |
| Ketoconazole | 287 |
| Betamethasone Valerate | 199 |
| Fluocinolone Acetonide Fluocinolone/Shower Cap | 173 |
| Ciclopirox | 154 |
| Hydrocortisone | 136 |
| Triamcinolone Acetonide | 134 |
| Cefadroxil | 119 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Dermatology Physician Overview
How LUIS ORTIZ-ESPINOSA, M.D., FAAD fits within the Dermatology Physician landscape nationally.
LUIS ORTIZ-ESPINOSA, M.D., FAAD's 4,701 claims are above the specialty average of 729.
Nearby Dermatology Physician Providers in Puerto Rico
Other clinicians with the same primary specialty enrolled in Puerto Rico, drawn from the same CMS NPPES roster as ORTIZ-ESPINOSA.
Compare Dermatology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Puerto Rico
Frequently Asked Questions
What is LUIS ORTIZ-ESPINOSA, M.D., FAAD's specialty? ▼
How much does LUIS ORTIZ-ESPINOSA, M.D., FAAD prescribe under Medicare Part D? ▼
What is LUIS ORTIZ-ESPINOSA, M.D., FAAD's Medicare quality score? ▼
Where is LUIS ORTIZ-ESPINOSA, M.D., FAAD located? ▼
What is LUIS ORTIZ-ESPINOSA, M.D., FAAD's NPI number? ▼
Does LUIS ORTIZ-ESPINOSA, M.D., FAAD prescribe more brand-name or generic drugs? ▼
How many Dermatology Physician providers are there in the US? ▼
What drugs does LUIS ORTIZ-ESPINOSA, M.D., FAAD prescribe most often? ▼
Does LUIS ORTIZ-ESPINOSA, M.D., FAAD accept Medicare? ▼
How can I verify LUIS ORTIZ-ESPINOSA, M.D., FAAD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology